Joint EANM/SNMMI procedure guideline for the use of
EANM/SNMMI
PSMA
[177Lu]Lu-PSMA-617
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
13
02
2023
accepted:
25
04
2023
medline:
5
7
2023
pubmed:
29
5
2023
entrez:
29
5
2023
Statut:
ppublish
Résumé
Prostate-specific membrane antigen (PSMA) is expressed by the majority of clinically significant prostate adenocarcinomas, and patients with target-positive disease can easily be identified by PSMA PET imaging. Promising results with PSMA-targeted radiopharmaceutical therapy have already been obtained in early-phase studies using various combinations of targeting molecules and radiolabels. Definitive evidence of the safety and efficacy of [
Identifiants
pubmed: 37246997
doi: 10.1007/s00259-023-06255-8
pii: 10.1007/s00259-023-06255-8
pmc: PMC10317889
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Radiopharmaceuticals
0
Heterocyclic Compounds, 1-Ring
0
Dipeptides
0
Lutetium
5H0DOZ21UJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2830-2845Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Informations de copyright
© 2023. The Author(s).
Références
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Schuchardt C, Zhang J, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-Specific Membrane Antigen Radioligand Therapy Using
doi: 10.2967/jnumed.121.262713
pubmed: 34887335
pmcid: 9364353
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91. https://doi.org/10.1158/1078-0432.CCR-13-0231 .
doi: 10.1158/1078-0432.CCR-13-0231
pubmed: 23714732
pmcid: 3778101
Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809. https://doi.org/10.1007/s00259-022-05727-7 .
doi: 10.1007/s00259-022-05727-7
pubmed: 35284969
pmcid: 9015994
IAEA nuclear data service. Live Chart of Nuclides, nuclear structure and decay data. https://www-nds.iaea.org/relnsd/vcharthtml/VChartHTML.html . Accessed 21 May 2023.
Sweat SD, Pacelli A, Murphy GP, Bostwick DG. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology. 1998;52(4):637–40. https://doi.org/10.1016/s0090-4295(98)00278-7 .
doi: 10.1016/s0090-4295(98)00278-7
pubmed: 9763084
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72. https://doi.org/10.1007/s12253-008-9104-2 .
doi: 10.1007/s12253-008-9104-2
pubmed: 18802790
Bakht MK, Derecichei I, Li Y, Ferraiuolo RM, Dunning M, Oh SW, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131–46. https://doi.org/10.1530/ERC-18-0226 .
doi: 10.1530/ERC-18-0226
pubmed: 30400059
Wright GL Jr, Haley C, Beckett ML, Schellhammer PF. Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol. 1995;1(1):18–28. https://doi.org/10.1016/1078-1439(95)00002-y .
doi: 10.1016/1078-1439(95)00002-y
pubmed: 21224086
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer. 1998;82(11):2256–61. https://doi.org/10.1002/(sici)1097-0142(19980601)82:11%3c2256::aid-cncr22%3e3.0.co;2-s .
Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, et al. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998;58(18):4055–60.
pubmed: 9751609
Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell. 2003;14(12):4835–45. https://doi.org/10.1091/mbc.e02-11-0731 .
doi: 10.1091/mbc.e02-11-0731
pubmed: 14528023
pmcid: 284788
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–18. https://doi.org/10.1200/JCO.2015.64.2702 .
doi: 10.1200/JCO.2015.64.2702
pubmed: 26903579
pmcid: 4872347
Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [
doi: 10.1016/S0140-6736(21)00237-3
pubmed: 33581798
Satapathy S, Mittal BR, Sood A, Das CK, Mavuduru RS, Goyal S, et al.
doi: 10.1007/s00259-021-05618-3
pubmed: 34842950
Calais J, Gafita A, Eiber M, Armstrong WR, Gartmann J, Thin P, et al. Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with
doi: 10.2967/jnumed.121.261982
pubmed: 34016732
pmcid: 8724893
Calais J, Czernin J, Thin P, Gartmann J, Nguyen K, Armstrong WR, et al. Safety of PSMA-targeted molecular radioligand therapy with
doi: 10.2967/jnumed.121.262543
pubmed: 34272322
pmcid: 8724902
Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Gorin MA, et al.
doi: 10.1002/pros.24325
pubmed: 35286735
pmcid: 9311733
Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80(1):82–94. https://doi.org/10.1016/j.eururo.2021.03.004 .
doi: 10.1016/j.eururo.2021.03.004
pubmed: 33840558
pmcid: 8206006
Ahmadzadehfar H, Rahbar K, Baum RP, Seifert R, Kessel K, Bögemann M, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [
doi: 10.1007/s00259-020-04797-9
pubmed: 32383093
Rosar F, Kochems N, Bartholomä M, Maus S, Stemler T, Linxweiler J, et al. Renal safety of [
doi: 10.3390/cancers13123095
pubmed: 34205686
Maffey-Steffan J, Scarpa L, Svirydenka A, Nilica B, Mair C, Buxbaum S, et al. The
doi: 10.1007/s00259-019-04583-2
pubmed: 31776632
Scarpa L, Buxbaum S, Kendler D, Fink K, Bektic J, Gruber L, et al. The
doi: 10.1007/s00259-016-3609-9
pubmed: 28083690
Derlin T, Sommerlath Sohns JM, Schmuck S, Henkenberens C, von Klot CAJ, Ross TL, Bengel FM. Influence of short-term dexamethasone on the efficacy of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Prostate. 2020;80(8):619–31. https://doi.org/10.1002/pros.23974 .
doi: 10.1002/pros.23974
pubmed: 32187729
Rasul S, Hacker M, Kretschmer-Chott E, Leisser A, Grubmüller B, Kramer G, et al. Clinical outcome of standardized
doi: 10.1007/s00259-019-04584-1
pubmed: 31781834
Rathke H, Giesel FL, Flechsig P, Kopka K, Mier W, Hohenfellner M, et al. Repeated
doi: 10.2967/jnumed.117.194209
pubmed: 28798031
Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. Delayed response after repeated
doi: 10.1007/s00259-017-3877-z
pubmed: 29134280
Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [
doi: 10.1007/s00259-017-3716-2
pubmed: 28488028
Kind F, Fassbender TF, Andrieux G, Boerries M, Meyer PT, Ruf J. Early PSA change after [
doi: 10.3390/cancers14010149
pubmed: 35008315
Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study. EJNMMI Res. 2015;5(1):114. https://doi.org/10.1186/s13550-015-0114-2 .
doi: 10.1186/s13550-015-0114-2
pubmed: 26099227
Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617. J Nucl Med. 2016;57(8):1170–6. https://doi.org/10.2967/jnumed.115.171397 .
doi: 10.2967/jnumed.115.171397
pubmed: 26985056
Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis. J Nucl Med. 2016;57(9):1334–8. https://doi.org/10.2967/jnumed.116.173757 .
doi: 10.2967/jnumed.116.173757
pubmed: 27056618
Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schäfers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. https://doi.org/10.2967/jnumed.116.183194 .
doi: 10.2967/jnumed.116.183194
pubmed: 27765862
Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [
doi: 10.18632/oncotarget.21600
pubmed: 29262549
pmcid: 5732715
Ahmadzadehfar H, Zimbelmann S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Radioligand therapy of metastatic prostate cancer using
doi: 10.18632/oncotarget.15698
pubmed: 28903443
pmcid: 5589682
Fendler WP, Reinhardt S, Ilhan H, Delker A, Böning G, Gildehaus FJ, et al. Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer. Oncotarget. 2017;8(2):3581–90. https://doi.org/10.18632/oncotarget.12240 .
doi: 10.18632/oncotarget.12240
pubmed: 27683041
Ferdinandus J, Eppard E, Gaertner FC, Kürpig S, Fimmers R, Yordanova A, et al. Predictors of response to radioligand therapy of metastatic castrate-resistant prostate cancer with 177Lu-PSMA-617. J Nucl Med. 2017;58(2):312–9. https://doi.org/10.2967/jnumed.116.178228 .
doi: 10.2967/jnumed.116.178228
pubmed: 27587707
Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, Rahbar K.
doi: 10.1007/s00259-017-3751-z
pubmed: 28624848
Rahbar K, Boegemann M, Yordanova A, Eveslage M, Schäfers M, Essler M, Ahmadzadehfar H. PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival. Eur J Nucl Med Mol Imaging. 2018;45(1):12–9. https://doi.org/10.1007/s00259-017-3848-4 .
doi: 10.1007/s00259-017-3848-4
pubmed: 29026946
Khurshid Z, Ahmadzadehfar H, Gaertner FC, Papp L, Zsóter N, Essler M, Bundschuh RA. Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction. Oncotarget. 2018;9(70):33312–21. https://doi.org/10.18632/oncotarget.26051 .
doi: 10.18632/oncotarget.26051
pubmed: 30279962
pmcid: 6161784
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [
doi: 10.1016/S1470-2045(18)30198-0
pubmed: 29752180
Grubmüller B, Senn D, Kramer G, Baltzer P, D’Andrea D, Grubmüller KH, et al. Response assessment using
doi: 10.1007/s00259-018-4236-4
pubmed: 30569186
Yadav MP, Ballal S, Bal C, Sahoo RK, Damle NA, Tripathi M, Seth A. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19–31. https://doi.org/10.1097/RLU.0000000000002833 .
doi: 10.1097/RLU.0000000000002833
pubmed: 31789908
Heinzel A, Boghos D, Mottaghy FM, Gaertner F, Essler M, von Mallek D, Ahmadzadehfar H.
doi: 10.1007/s00259-019-4258-6
pubmed: 30697649
van Kalmthout L, Braat A, Lam M, van Leeuwaarde R, Krijger G, Ververs T, et al. First experience with 177Lu-PSMA-617 therapy for advanced prostate cancer in the Netherlands. Clin Nucl Med. 2019;44(6):446–51. https://doi.org/10.1097/RLU.0000000000002561 .
doi: 10.1097/RLU.0000000000002561
pubmed: 30985436
Kessel K, Seifert R, Schäfers M, Weckesser M, Schlack K, Boegemann M, Rahbar K. Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
doi: 10.7150/thno.35759
pubmed: 31410185
pmcid: 6691377
McBean R, O’Kane B, Parsons R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019;63(4):538–45. https://doi.org/10.1111/1754-9485.12891 .
doi: 10.1111/1754-9485.12891
pubmed: 31021525
Yordanova A, Linden P, Hauser S, Meisenheimer M, Kürpig S, Feldmann G, et al. Outcome and safety of rechallenge [
doi: 10.1007/s00259-018-4222-x
pubmed: 30474706
Gupta M, Choudhury PS, Rawal S, Karthikeyan G, Talwar V, Dutta KD, Singh A. Safety profile and therapeutic efficacy of one cycle of Lu177-PSMA in end-stage metastatic castration-resistant prostate cancer patients with low performance status. Nucl Med Mol Imaging. 2019;53(6):423–31. https://doi.org/10.1007/s13139-019-00624-8 .
doi: 10.1007/s13139-019-00624-8
pubmed: 31867078
pmcid: 6898708
Emmett L, Crumbaker M, Ho B, Willowson K, Eu P, Ratnayake L, et al. Results of a prospective phase 2 pilot trial of
doi: 10.1016/j.clgc.2018.09.014
pubmed: 30425003
Aghdam RA, Amoui M, Ghodsirad M, Khoshbakht S, Mofid B, Kaghazchi F, et al. Efficacy and safety of
doi: 10.4103/wjnm.WJNM_66_18
pubmed: 31516369
pmcid: 6714159
Assadi M, Rezaei S, Jafari E, Rekabpour SJ, Ravanbod MR, Zohrabi F, et al. Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years. World J Nucl Med. 2020;19(1):15–20. https://doi.org/10.4103/wjnm.WJNM_20_19 .
doi: 10.4103/wjnm.WJNM_20_19
pubmed: 32190017
pmcid: 7067127
Derlin T, Werner RA, Lafos M, Henkenberens C, von Klot CAJ, Sommerlath Sohns JM, et al. Neuroendocrine differentiation and response to PSMA-targeted radioligand therapy in advanced metastatic castration-resistant prostate cancer: a single-center retrospective study. J Nucl Med. 2020;61(11):1602–6. https://doi.org/10.2967/jnumed.120.241588 .
doi: 10.2967/jnumed.120.241588
pubmed: 32169910
Gadot M, Davidson T, Aharon M, Atenafu EG, Malki A, Levartovsky M, et al. Clinical variables associated with PSA response to lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer. Cancers (Basel). 2020;12(5):1078. https://doi.org/10.3390/cancers12051078 .
doi: 10.3390/cancers12051078
pubmed: 32357427
Gafita A, Fendler WP, Hui W, Sandhu S, Weber M, Esfandiari R, et al. Efficacy and safety of
doi: 10.1016/j.eururo.2020.05.004
pubmed: 32532512
Gupta M, Karthikeyan G, Choudhury PS, Sharma A, Singh A, Rawal S. Is
doi: 10.1967/s002449912219
pubmed: 33367303
Leibowitz R, Davidson T, Gadot M, Aharon M, Malki A, Levartovsky M, et al. A retrospective analysis of the safety and activity of lutetium-177-prostate-specific membrane antigen radionuclide treatment in older patients with metastatic castration-resistant prostate cancer. Oncologist. 2020;25(9):787–92. https://doi.org/10.1634/theoncologist.2020-0100 .
doi: 10.1634/theoncologist.2020-0100
pubmed: 32430954
pmcid: 7485364
Marinova M, Alamdar R, Ahmadzadehfar H, Essler M, Attenberger U, Mücke M, Conrad R. Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study. Nuklearmedizin. 2020;59(6):409–14. https://doi.org/10.1055/a-1234-5891 .
doi: 10.1055/a-1234-5891
pubmed: 32823294
Rathke H, Holland-Letz T, Mier W, Flechsig P, Mavriopoulou E, Röhrich M, et al. Response prediction of
doi: 10.2967/jnumed.119.231431
pubmed: 31653712
Seifert R, Kessel K, Schlack K, Weckesser M, Bögemann M, Rahbar K. Radioligand therapy using [
doi: 10.1007/s00259-020-04703-3
pubmed: 32062682
pmcid: 7338828
Paganelli G, Sarnelli A, Severi S, Sansovini M, Belli ML, Monti M, et al. Dosimetry and safety of
doi: 10.1007/s00259-020-04856-1
pubmed: 32430583
Violet J, Sandhu S, Iravani A, Ferdinandus J, Thang SP, Kong G, et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of
doi: 10.2967/jnumed.119.236414
pubmed: 31732676
pmcid: 7262220
Khreish F, Kochems N, Rosar F, Sabet A, Ries M, Maus S, et al. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
doi: 10.1007/s00259-020-04828-5
pubmed: 32378019
Michalski K, Klein C, Brueggemann T, Meyer PT, Jilg CA, Ruf J. Assessing response to [
doi: 10.2967/jnumed.120.260836
pubmed: 33789932
pmcid: 8612188
Prasad V, Huang K, Prasad S, Makowski MR, Czech N, Brenner W. In comparison to PSA, interim Ga-68-PSMA PET/CT response evaluation based on modified RECIST 1.1 after 2nd cycle is better predictor of overall survival of prostate cancer patients treated with 177Lu-PSMA. Front Oncol. 2021;11:578093. https://doi.org/10.3389/fonc.2021.578093 .
doi: 10.3389/fonc.2021.578093
pubmed: 33816225
pmcid: 8010239
Rasul S, Hartenbach M, Wollenweber T, Kretschmer-Chott E, Grubmüller B, Kramer G, et al. Prediction of response and survival after standardized treatment with 7400 MBq
doi: 10.1007/s00259-020-05082-5
pubmed: 33128131
Rasul S, Wollenweber T, Zisser L, Kretschmer-Chott E, Grubmüller B, Kramer G, et al. Response and toxicity to the second course of 3 cycles of
doi: 10.3390/cancers13102489
pubmed: 34065303
Tatkovic A, McBean R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: 18 months survival analysis in a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2021;65(6):740–7. https://doi.org/10.1111/1754-9485.13182 .
doi: 10.1111/1754-9485.13182
pubmed: 33890406
Widjaja L, Werner RA, Ross TL, Bengel FM, Derlin T. PSMA expression predicts early biochemical response in patients with metastatic castration-resistant prostate cancer under
doi: 10.3390/cancers13122938
pubmed: 34208246
Privé BM, Peters SMB, Muselaers CHJ, van Oort IM, Janssen MJR, Sedelaar JPM, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clin Cancer Res. 2021;27(13):3595–601. https://doi.org/10.1158/1078-0432.CCR-20-4298 .
doi: 10.1158/1078-0432.CCR-20-4298
pubmed: 33883176
Yadav MP, Ballal S, Sahoo RK, Tripathi M, Damle NA, Shamim SA, et al. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients. PLoS One. 2021;16(5):e0251375. https://doi.org/10.1371/journal.pone.0251375 .
doi: 10.1371/journal.pone.0251375
pubmed: 33970962
pmcid: 8109776
Khreish F, Ghazal Z, Marlowe RJ, Rosar F, Sabet A, Maus S, et al. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: initial 254-patient results from a prospective registry (REALITY Study). Eur J Nucl Med Mol Imaging. 2022;49(3):1075–85. https://doi.org/10.1007/s00259-021-05525-7 .
doi: 10.1007/s00259-021-05525-7
pubmed: 34494131
Barber TW, Singh A, Kulkarni HR, Niepsch K, Billah B, Baum RP. Clinical outcomes of
doi: 10.2967/jnumed.118.216820
pubmed: 30683770
Gallyamov M, Meyrick D, Barley J, Lenzo N. Renal outcomes of radioligand therapy: experience of
doi: 10.1093/ckj/sfz101
pubmed: 33391748
pmcid: 7769531
Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016;57(7):1006–13. https://doi.org/10.2967/jnumed.115.168443 .
doi: 10.2967/jnumed.115.168443
pubmed: 26795286
Heck MM, Tauber R, Schwaiger S, Retz M, D’Alessandria C, Maurer T, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with
doi: 10.1016/j.eururo.2018.11.016
pubmed: 30473431
Kesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, Lenzo NP. Salvage radiopeptide therapy of advanced castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen: efficacy and safety in routine practice. Cancer Biother Radiopharm. 2018;33(7):274–81. https://doi.org/10.1089/cbr.2017.2403 .
doi: 10.1089/cbr.2017.2403
pubmed: 29989440
Kletting P, Thieme A, Eberhardt N, Rinscheid A, D’Alessandria C, Allmann J, et al. Modeling and predicting tumor response in radioligand therapy. J Nucl Med. 2019;60(1):65–70. https://doi.org/10.2967/jnumed.118.210377 .
doi: 10.2967/jnumed.118.210377
pubmed: 29748236
Acar E, Özdoğan Ö, Aksu A, Derebek E, Bekiş R, Çapa KG. The use of molecular volumetric parameters for the evaluation of Lu-177 PSMA I&T therapy response and survival. Ann Nucl Med. 2019;33(9):681–8. https://doi.org/10.1007/s12149-019-01376-3 .
doi: 10.1007/s12149-019-01376-3
pubmed: 31214958
Bülbül O, Ünek İT, Kefi A, Tuna EB, Bekiş R. Factors affecting overall survival and progression-free survival in patients with metastatic castration resistant prostate cancer received
doi: 10.1967/s002449912201
pubmed: 33306752
Barna S, Haug AR, Hartenbach M, Rasul S, Grubmüller B, Kramer G, Blaickner M. Dose calculations and dose-effect relationships in 177Lu-PSMA I&T radionuclide therapy for metastatic castration-resistant prostate cancer. Clin Nucl Med. 2020;45(9):661–7. https://doi.org/10.1097/RLU.0000000000003157 .
doi: 10.1097/RLU.0000000000003157
pubmed: 32604113
Kesavan M, Meyrick D, Gallyamov M, Turner JH, Yeo S, Cardaci G, Lenzo NP. Efficacy and haematologic toxicity of palliative radioligand therapy of metastatic castrate-resistant prostate cancer with lutetium-177-labeled prostate-specific membrane antigen in heavily pre-treated patients. Diagnostics (Basel). 2021;11(3):515. https://doi.org/10.3390/diagnostics11030515 .
doi: 10.3390/diagnostics11030515
pubmed: 33799431
Taylor AT, Brandon DC, de Palma D, Blaufox MD, Durand E, Erbas B, et al. SNMMI Procedure Standard/EANM Practice Guideline for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction 1.0. Semin Nucl Med. 2018;48(4):377–90. https://doi.org/10.1053/j.semnuclmed.2018.02.010 .
doi: 10.1053/j.semnuclmed.2018.02.010
pubmed: 29852947
pmcid: 6020824
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, et al. Therapeutic efficacy, prognostic variables and clinical outcome of
doi: 10.1259/bjr.20190380
pubmed: 31600089
pmcid: 6913363
Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after
doi: 10.1016/S1470-2045(21)00274-6
pubmed: 34246328
Heidegger I, Kesch C, Kretschmer A, Tsaur I, Ceci F, Valerio M, et al. Biomarkers to personalize treatment with 177Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer - a state of the art review. Ther Adv Med Oncol. 2022;14:17588359221081922. https://doi.org/10.1177/17588359221081922 .
doi: 10.1177/17588359221081922
pubmed: 35273651
pmcid: 8902011
Peters SMB, Hofferber R, Privé BM, de Bakker M, Gotthardt M, Janssen M, et al. [
doi: 10.1007/s00259-021-05538-2
pubmed: 34623453
Peters SMB, Privé BM, de Bakker M, de Lange F, Jentzen W, Eek A, et al. Intra-therapeutic dosimetry of [
doi: 10.1007/s00259-021-05471-4
pubmed: 34218300
Völter F, Mittlmeier L, Gosewisch A, Brosch-Lenz J, Gildehaus FJ, Zacherl MJ, et al. Correlation of an index-lesion-based SPECT dosimetry method with mean tumor dose and clinical outcome after
doi: 10.3390/diagnostics11030428
pubmed: 33802417
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of
doi: 10.2967/jnumed.118.219352
pubmed: 30291192
Herrmann K, Kraus BJ, Hadaschik B, Kunikowska J, van Poppel H, N’Dow J, et al. Nuclear medicine theranostics comes of age. Lancet Oncol. 2021;22(11):1497–8. https://doi.org/10.1016/S1470-2045(21)00540-4 .
doi: 10.1016/S1470-2045(21)00540-4
pubmed: 34735807
Calais J, Czernin J. PSMA expression assessed by PET imaging is a required biomarker for selecting patients for any PSMA-targeted therapy. J Nucl Med. 2021;62(11):1489–91. https://doi.org/10.2967/jnumed.121.263159 .
doi: 10.2967/jnumed.121.263159
pubmed: 34725231
pmcid: 8612346
Kuo PH, Benson T, Messmann R, Groaning M. Why we did what we did: PSMA PET/CT selection criteria for the VISION Trial. J Nucl Med. 2022;63(6):816–8. https://doi.org/10.2967/jnumed.121.263638 .
doi: 10.2967/jnumed.121.263638
pubmed: 35086895
Stangl-Kremser J, Rasul S, Tosoian JJ, Salami SS, Zaslavsky A, Udager A, et al. Single-lesion prostate-specific membrane antigen protein expression (PSMA) and response to [
doi: 10.1016/j.euros.2021.06.007
pubmed: 34337549
pmcid: 8317820
Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76(4):469–78. https://doi.org/10.1016/j.eururo.2019.06.030 .
doi: 10.1016/j.eururo.2019.06.030
pubmed: 31345636
pmcid: 6853166
Hotta M, Gafita A, Murthy V, Benz MR, Sonni I, Burger I, et al. Predicting the outcome of mCPRC patients after Lu-177 PSMA therapy using semi-quantitative and visual criteria in baseline PSMA PET: an international multicenter retrospective study. J Clin Oncol. 2022;40(6):32–32. https://doi.org/10.1200/JCO.2022.40.6_suppl.032 .
doi: 10.1200/JCO.2022.40.6_suppl.032
Hotta M, Gafita A, Czernin J, Calais J. Outcome of patients with PSMA-PET/CT screen failure by VISION criteria and treated with
doi: 10.2967/jnumed.121.263441
pubmed: 36581376
Okamoto S, Thieme A, Allmann J, D’Alessandria C, Maurer T, Retz M, et al. Radiation dosimetry for
doi: 10.2967/jnumed.116.178483
pubmed: 27660138
Suman S, Parghane RV, Joshi A, Prabhash K, Talole S, Basu S. Combined
doi: 10.1002/pros.24219
pubmed: 34469602
Sjögreen Gleisner K, Chouin N, Gabina PM, Cicone F, Gnesin S, Stokke C, et al. EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. Eur J Nucl Med Mol Imaging. 2022;49(6):1778–809. https://doi.org/10.1007/s00259-022-05727-7 .
doi: 10.1007/s00259-022-05727-7
pubmed: 35284969
pmcid: 9015994
Soydal C, Araz M, Urun Y, Nak D, Ozkan E, Kucuk NO. Prognostic importance of prostatic specific antigen response in patients who received lutetium-177 prostate-specific membrane antigen treatment for castration resistant prostate cancer. Q J Nucl Med Mol Imaging. 2021;65(3):282–6. https://doi.org/10.23736/S1824-4785.19.03165-0 .
doi: 10.23736/S1824-4785.19.03165-0
pubmed: 31602963
Rathke H, Kratochwil C, Hohenberger R, Giesel FL, Bruchertseifer F, Flechsig P, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing
doi: 10.1007/s00259-018-4135-8
pubmed: 30151743
Mahajan S, Grewal RK, Friedman KP, Schöder H, Pandit-Taskar N. Assessment of salivary gland function after 177Lu-PSMA radioligand therapy: current concepts in imaging and management. Transl Oncol. 2022;21:101445. https://doi.org/10.1016/j.tranon.2022.101445 .
doi: 10.1016/j.tranon.2022.101445
pubmed: 35523007
pmcid: 9079342
Full prescribing information for PLUVICTO; FDA 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf?msclkid=d4809f3cab3e11ecbf5d1db14a168354 . Accessed 21 May 2023.
Herrmann K, Rahbar K, Eiber M, Krause BJ, Lassmann M, Jentzen W, et al. Dosimetry of
doi: 10.1200/JCO.2022.40.6_suppl.097
Jackson PA, Hofman MS, Hicks RJ, Scalzo M, Violet J. Radiation dosimetry in
doi: 10.2967/jnumed.119.233411
pubmed: 31806772
pmcid: 7383083
Kabasakal L, AbuQbeitah M, Aygün A, Yeyin N, Ocak M, Demirci E, Toklu T. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976–83. https://doi.org/10.1007/s00259-015-3125-3 .
doi: 10.1007/s00259-015-3125-3
pubmed: 26227531
Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42–51. https://doi.org/10.1007/s00259-015-3174-7 .
doi: 10.1007/s00259-015-3174-7
pubmed: 26318602
Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18(3):437–45. https://doi.org/10.1007/s11307-016-0942-0 .
doi: 10.1007/s11307-016-0942-0
pubmed: 26920354
Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, Bal C. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38(1):91–8. https://doi.org/10.1097/MNM.0000000000000606 .
doi: 10.1097/MNM.0000000000000606
pubmed: 27782913
Kabasakal L, Toklu T, Yeyin N, Demirci E, Abuqbeitah M, Ocak M, et al. Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry. Mol Imaging Radionucl Ther. 2017;26(2):62–8. https://doi.org/10.4274/mirt.08760 .
doi: 10.4274/mirt.08760
pubmed: 28613198
pmcid: 5472088
Khawar A, Eppard E, Sinnes JP, Roesch F, Ahmadzadehfar H, Kürpig S, et al. Prediction of normal organ absorbed doses for [177Lu]Lu-PSMA-617 using [44Sc]Sc-PSMA-617 pharmacokinetics in patients with metastatic castration resistant prostate carcinoma. Clin Nucl Med. 2018;43(7):486–91. https://doi.org/10.1097/RLU.0000000000002102 .
doi: 10.1097/RLU.0000000000002102
pubmed: 29688951
Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA
doi: 10.1186/s13550-018-0427-z
pubmed: 30076556
pmcid: 6081875
Sarnelli A, Belli ML, Di Iorio V, Mezzenga E, Celli M, Severi S, et al. Dosimetry of
doi: 10.3390/molecules24030621
pubmed: 30754620
pmcid: 6385027
Wang J, Zang J, Wang H, Liu Q, Li F, Lin Y, et al. Pretherapeutic 68Ga-PSMA-617 PET may indicate the dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in main organs and tumor lesions. Clin Nucl Med. 2019;44(6):431–8. https://doi.org/10.1097/RLU.0000000000002575 .
doi: 10.1097/RLU.0000000000002575
pubmed: 30985422
pmcid: 6502681
Gosewisch A, Ilhan H, Tattenberg S, Mairani A, Parodi K, Brosch J, et al. 3D Monte Carlo bone marrow dosimetry for Lu-177-PSMA therapy with guidance of non-invasive 3D localization of active bone marrow via Tc-99m-anti-granulocyte antibody SPECT/CT. EJNMMI Res. 2019;9(1):76. https://doi.org/10.1186/s13550-019-0548-z .
doi: 10.1186/s13550-019-0548-z
pubmed: 31414241
pmcid: 6694348
Götz TI, Lang EW, Prante O, Cordes M, Kuwert T, Ritt P, et al. Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer. Nuklearmedizin. 2020;59(5):365–74. https://doi.org/10.1055/a-1204-9932 .
doi: 10.1055/a-1204-9932
pubmed: 32663888
Kamaldeep, Wanage G, Sahu SK, Maletha P, Adnan A, Suman S, et al. Examining absorbed doses of indigenously developed
doi: 10.1089/cbr.2020.3640
pubmed: 32379495
Rosar F, Schön N, Bohnenberger H, Bartholomä M, Stemler T, Maus S, et al. Comparison of different methods for post-therapeutic dosimetry in [
doi: 10.1186/s40658-021-00385-4
pubmed: 33950333
pmcid: 8099965
Kurth J, Heuschkel M, Tonn A, Schildt A, Hakenberg OW, Krause BJ, Schwarzenböck SM. Streamlined schemes for dosimetry of
doi: 10.3390/cancers13153884
pubmed: 34359784
Mahmoudi E, Pirayesh E, Deevband MR, Amoui M, Rad MG, Ghorbani M. Patient-specific dosimetry in radioligand therapy (RLT) for metastatic prostate cancer using
doi: 10.1007/s13139-021-00713-7
pubmed: 34721716
pmcid: 8517055
Mix M, Renaud T, Kind F, Nemer U, Yousetzadeh-Nowsha E, Moalosi TCG, et al. Kidney doses in
doi: 10.2967/jnumed.121.262245
pubmed: 34088773
Rinscheid A, Kletting P, Eiber M, Beer AJ, Glatting G. Influence of sampling schedules on [
doi: 10.1186/s40658-020-00311-0
pubmed: 32556844
pmcid: 7300169
Brosch-Lenz J, Uribe C, Gosewisch A, Kaiser L, Todica A, Ilhan H, et al. Influence of dosimetry method on bone lesion absorbed dose estimates in PSMA therapy: application to mCRPC patients receiving Lu-177-PSMA-I&T. EJNMMI Phys. 2021;8(1):26. https://doi.org/10.1186/s40658-021-00369-4 .
doi: 10.1186/s40658-021-00369-4
pubmed: 33709253
pmcid: 7952490
Chatachot K, Shiratori S, Chaiwatanarat T, Khamwan K. Patient dosimetry of
doi: 10.1007/s12149-021-01659-8
pubmed: 34309816
Feuerecker B, Chantadisai M, Allmann A, Tauber R, Allmann J, Steinhelfer L, et al. Pretherapeutic comparative dosimetry of 177Lu-rhPSMA-7.3 and 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2022;63(6):833–9. https://doi.org/10.2967/jnumed.121.262671 .
doi: 10.2967/jnumed.121.262671
pubmed: 34531260
pmcid: 9157737
Nautiyal A, Jha AK, Mithun S, Rangarajan V. Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review. Nucl Med Commun. 2022;43(4):369–77. https://doi.org/10.1097/MNM.0000000000001535 .
doi: 10.1097/MNM.0000000000001535
pubmed: 35045551
Konijnenberg M, Herrmann K, Kobe C, Verburg F, Hindorf C, Hustinx R, Lassmann M. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging. 2021;48(1):67–72. https://doi.org/10.1007/s00259-020-05038-9 .
doi: 10.1007/s00259-020-05038-9
pubmed: 33057773
Filss C, Heinzel A, Miiller B, Vogg ATJ, Langen KJ, Mottaghy FM. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Nuklearmedizin. 2018;57(1):19–25. https://doi.org/10.3413/Nukmed-0937-17-10 .
doi: 10.3413/Nukmed-0937-17-10
pubmed: 29536496
Tuncel M, Telli T, Tuncalı MÇ, Karabulut E. Predictive factors of tumor sink effect: insights from
doi: 10.1007/s12149-021-01593-9
pubmed: 33586096